Heron Therapeutics (HRTX) Price to Earnings (2011 - 2026)

Heron Therapeutics (HRTX) has reported Price to Earnings for 16 consecutive years, with 39.94 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings rose 79.37% year-over-year to 39.94; the trailing twelve-month figure through Jun 2026 stood at 9.16 (down 113.82% YoY), and the FY2025 full-year result was 24.01, down 44.54% from the prior year.
• Price to Earnings retreated to 39.94 in Q2 2026 per HRTX's latest filing, from 31.71 in the prior quarter.
• Across five years, Price to Earnings topped out at 122.47 in Q4 2025 and bottomed at 193.6 in Q2 2025.
• Historically, Price to Earnings has averaged 21.97 across 5 years, with a median of 13.96 in 2022.
• The sharpest annual moves came in 2024 and 2025: Price to Earnings slumped 2039.04% in 2024, then jumped 304.93% in 2025.
• Over 5 years, Price to Earnings stood at 15.96 in 2022, then slumped by 132.89% to 37.17 in 2023, then jumped by 181.37% to 30.24 in 2024, then jumped by 304.93% to 122.47 in 2025, then sank by 132.61% to 39.94 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 39.94, 31.71, and 122.47 for Q2 2026, Q1 2026, and Q4 2025 respectively.